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Background: Worldwide, oral squamous cell carcinoma (potentially mediated by HER2) is 
recognized as the most commonly occurring malignant neoplasm of the oral cavity. Anti-HER2 
nanobodies conjugated to gold-silica nanoshells and used as photothermal treatment for oral 
squamous cell carcinoma may provide a novel therapeutic alternative to current treatment for 
this disease.
Methods: KB epithelial or HeLaS3 cell cultures (controls) were exposed to these immu-
nonanoshells, and plasmon resonance electron initiation specific to gold was employed to burn 
the tumor cells.
Results: Following this treatment, significant cell death occurred in the KB tumor cell cultures 
while there was no evidence of cellular damage or death in the HeLaS3 cell cultures.
Conclusion: These findings suggest that photothermal treatment of oral squamous cell 
carcinoma has considerable advantages.
Keywords: anti-HER2 immunonanoshells, gold-silica nanoshells, photothermal treatment, 
oral squamous cell carcinoma
Introduction
Oral squamous cell carcinoma is histopathologically characterized by invasive 
islands of malignant squamous epithelial cells, and accounts for more than 90% of all 
malignant neoplasms of the oral cavity. The majority of these cancers are located on 
the tongue, mainly at the lateral posterior border.1,2 Current treatments are based on 
the clinical stage of the disease and may include surgical excision, radiation therapy, 
chemotherapy, or combination therapy, as well as new investigational methods such 
as immunotherapy or gene therapy.1,3,4 Surgical excision can result in complications, 
and the use of conventional radiotherapy may cause an oral cavity disorder, resulting 
in reduced patient survival time.5 Because local carcinoma recurrences are common 
and current treatments can result in significant problems, alternative therapeutic 
approaches are warranted.6
Thermal therapy is emerging as a promising alternative strategy that is simple 
to perform and is advantageous as an alternative treatment for certain malignancies. 
The use of hyperthermia in the treatment of a variety of solid tumors has been under 
investigation for quite some time.7–13
When generating nanoshells, it is possible to manipulate the size and layer of their 
composition and to conjugate antibodies with the nanoshells to target cancerous cells 
specifically.14–16 The nanoshells neither absorb nor scatter light emission, thereby International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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allowing local destruction of tumor tissue.14,17,18 It is also 
possible to construct gold nanoshells that preferentially 
absorb light in the near infrared region of the spectrum 
(700–1100 nm) so that optical transmission through tissue is 
optimal.19 This property could be used for noninvasive excita-
tion of nanoshells within tissue. Using antibody conjugation 
to target nanoparticle-encapsulated drugs to tumor sites has 
increasingly been incorporated as a therapeutic approach in 
cancer.20 A relatively high incidence of endothelial growth 
factor receptor and HER2 overexpression has been reported 
in oral squamous cell carcinoma.21–23
A previous study demonstrated that nanoshells injected 
into mice could accumulate at tumor sites because of the 
small size of the nanoparticles and enhanced permeability 
and retention effects.24 Following near-infrared laser 
irradiation to introduce cellular hyperthermia, tumors were 
completely eliminated. Neutron activation analysis has 
been used to detect and qualify gold (nanoshells) in blood, 
bone, and other tissues, and has been used to determine 
nanoshell concentrations in tumors.25 Further, the nanoshell 
is composed of substances (silica, gold, and targeting 
antibodies) that have also been used previously as nontoxic 
pharmacological agents. In this study, for the first time, 
the efficacy of photothermal treatment/near-infrared laser 
light with anti-HER2 nanobody-conjugated nanoshells 
was investigated in an in vitro model of oral squamous cell 
carcinoma.
Materials and methods
cell lines and cell culture
All cell lines were obtained from the cell bank at the Pasteur 
Institute of Iran. HER2-positive KB cells were grown in 
RPMI 1640 medium (Gibco-Invitrogen Corporation, Auck-
land, New Zealand). HER2-negative HeLaS3 cells were 
grown in HAM F12 medium (Gibco-Invitrogen Corpora-
tion). All media were supplemented with 10% fetal bovine 
serum and 1% antibiotics (90 U/mL penicillin and 0.9 µg/
mL streptomycin).The cell cultures were maintained at 37°C 
in a humidified incubator under 5% CO2.
gold-silica nanoshell fabrication
The nanoshells were fabricated as previously described.26,27 
All chemicals were purchased from Merck, Hohenbrunn, 
Germany. Three milliliters of 30% ammonia solution was 
mixed with 50 mL of absolute ethanol. After this,1.5 mL of 
tetraethyl orthosilicate 6.7 mM was added, and the solution 
was stirred overnight. The silica nanoparticles produced 
during this process were 100 nm in diameter. Treatment 
with organosilane produced surface-containing terminal 
amine groups. To make the nanoparticles functional, we 
mixed 50 µL of 0.28 mM organosilane with the silica nano-
particles. Following an overnight reaction, the solution was 
kept at a low boil for one hour to facilitate covalent bonding 
of organosilane to the surface of the silica nanoparticles. 
We then added dry ethanol gradually to maintain a constant 
volume. The solution was centrifuged at 2000 rpm per minute 
at 4°C for 30 minutes and redispersed in ethanol at least five 
times to remove excess materials.
For preparation of the gold nanoparticles, we rapidly 
mixed 45 mL of high-pressure liquid chromatography grade 
water with 0.5 mL NaOH, 1 mL tetrakis (hydroxymethyl) 
phosphonium chloride and 1.5 mL HAuCL4 into a 1% H2O 
solution with vigorous stirring. The gold nanoparticles 
produced were approximately 3 nm in diameter, and were 
prepared as previously described by Duff et al and stored 
for two weeks at 6°C.28 Following a 2-week incubation, 
25 mg of K2CO3 dissolved in 100 mL water was added, and 
1.5 mL of 1% 2-chloroauric acid was then vigorously mixed 
into the solution. Four milliliters of this solution was mixed 
with 100 mL of silica-gold nanoparticles. Finally, 10 µL of 
0.36 mM formaldehyde was added, turning the solution dark 
blue. This solution was then centrifuged at 2000 rpm per 
minute at 4°C for 30 minutes and redispersed in high-pressure 
liquid chromatography grade water at least twice to remove 
excess materials. The final estimation of the nanoshells 
was determined by optical absorption profiling using an 
ultraviolet-visible spectrophotometer (3100; Shimadzu, 
Tokyo, Japan). The dimensions of the nanoshells were 
assessed by electron microscopy (EM-900, 800 Kev; Zeiss, 
Oberkochen, Germany). The nanoshells used in this study 
were approximately 100 nm in diameter with a 10 nm thick 
gold shell and displayed an extinction peak at 820 nm.
Nanoshells anti-her2 nanobody 
conjugation
Approximately 8 × 108 nanoshells were suspended in a 
K2CO3 solution (0.2 M, pH 8.2–8.8) at a final concentration 
of 8 µg /mL of SR-86 nanobody and then stirred gently 
using a stirrer magnet bar at room temperature. Next, 20 µL 
of 1% polyethylene glycol (molecular weight 20,000) was 
added per mL of solution and stirred gently for 5 minutes 
at room temperature. A 20 µL sample of 10% bovine serum 
albumin solution in phosphate-buffered saline (pH 7.2–7.4) 
was added for each milliliter of suspension and gently 
stirred for 5 minutes. The solution was poured into a tube 
(Sigma 3K30 Laborzentrifugen, Germany) and centrifuged International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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at 14,000 g for 45 minutes at 4°C to remove excess reagents, 
such as unbound nanoshells or nanobodies. Following 
centrifugation, we removed 4.5 mL of supernatant and 
resolved the pellet in 20 µL of 1% bovine serum albumin in 
phosphate-buffered saline (pH 7.2–7.4) per mL of solution 
with gentle stirring for 5 minutes. The solution was then 
centrifuged at 14,000 g for 45 minutes at 4°C. This step 
was then repeated, with the centrifugation step reduced to 
30 minutes. The pellet was resuspended in 1% bovine serum 
albumin and stored at 4°C.
Molecular imaging of her2 expression 
and in vitro photothermal therapy
Cells were seeded onto 96-well plates at a density of 5 × 103 
cells/cm2 and grown until nearly confluent. Images were 
taken with a Zeiss fluorescence microscope before and after 
laser irradiation. Cells were washed with phosphate-buffered 
saline twice, and 8 × 108 nanoshells/mL were mixed with cell 
culture media without fetal bovine serum at an 8:1 ratio. The 
culture medium was removed from each well, and replaced 
with 100 µL of the nanoshell solution. After one hour of 
incubation at 37°C under 5% CO2, the cells were washed 
three times with phosphate-buffered saline to remove the 
unbound nanoshells. Next, a 4 mm diameter spot in each well 
was exposed to laser light (Med Art, Hvidovre, Denmark) 
at 820 nm and 4 W/cm2 for two minutes. Eight hours later, 
the cells were examined using the MTT assay.29 A 50 µL 
sample of MTT dye (Merck, 10 mg/mL in phosphate-
buffered saline) was added to each well. The plates were 
incubated at 37°C for three hours and then centrifuged at 
800 g for 10 minutes. Finally, the supernatant was aspirated. 
Formazan production was determined one hour after addition 
of 100 µL of dimethyl sulfoxide (Merck) using an enzyme-
linked immunosorbent assay microplate reader (Labsystem, 
Multiskan MS, England) at 575 nm.
Results
Production of gold-silica nanoshells
The gold-silica nanoshells were produced as previously 
described, and aliquots were conjugated to a targeting 
antibody. The extra sites on the nanoshells were blocked by 
adding a solution of bovine serum albumin. Figure 1 indicates 
that the absorption spectra of the bare nanoshells were 
nearly identical. The antibody did not have any detectable 
adsorption in the near-infrared region, indicating that the 
optical properties of the nanoshells must originate from the 
bare nanoshells. This finding suggests that the properties of 
the nanoshells were not altered by antibody conjugation or 
addition of bovine serum albumin. We visualized the gold-
silica nanoshells using transmission electron microscopy 
(Figure 2).
her2-targeted nanoshells in KB  
and heLas3 cell lines
As expected, bare nanoshells could be absorbed nonspe-
cifically to the cell surface in both cell lines. Nonspecific 
attachment of the bare nanoshells could induce cell death in 
the area treated with laser, but cell mortality was low in the 
KB and HeLaS3 cells.
her2-targeted nanobody-conjugated 
nanoshells in KB and heLas3 cells
The nanoshells conjugated to nanobodies were able to induce 
cell death effectively in KB cells overexpressing HER2 on 
their surface. The specificity and affinity of binding was 
900 800 700
Wavelength (nm)
A
b
s
o
r
b
a
n
c
e
600 500 400
0.25
0.50
0.75
1.00
1000
Figure 1 spectral characteristics of near-infrared-absorbing nanoshells. The absorption 
spectrum  shows  the  absorbing  near-infrared  nature  (820  nm)  of  nanoshells  with 
dimensions consisting of a silica core of 100 nm in diameter and shells approximately 
10 nm thick. Predicted optical properties were confirmed using ultraviolet-visible 
spectrophotometry.
Figure 2 Transmission electron microscopic image of gold-silica nanoshells with an 
overall diameter of 111 ± 3 nm. 
Note: scale bar = 100 nm.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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confirmed previously by antibodies and antigen-based 
studies.22 A comparison of the images demonstrated 
the relationship between nanoshell absorption and cell 
cytotoxicity following laser treatment (Figure 3A and B 
versus Figure 4A and B).
Viability staining
A cell viability staining experiment29 was performed in all 
the experimental groups. These assays were used to evaluate 
the number of living cells following near-infrared radiation. 
Each cell line was divided in four groups, and the viability 
of each group of cells was evaluated by the MTT assay 
  (Figures 5–8). Nonspecific binding was responsible for 0.6%–
1.5% of cell death in KB cells while this number was slightly 
lower at 0.3%–0.9% in HeLaS3 cells (Figures 6 and 7). 
The highest mortality was observed in KB cells (69.4%) 
following addition of the nanobody-nanoshell conjugates 
and subsequent exposure to laser radiation.   Mortality was 
much lower in the HeLaS3 cells, at approximately 4% 
(Figure 8). It should be noted that there was loss of both viable 
and dead cells due to reagent removal and washing during 
the experiment. It should be noted that there was a significant 
difference between all experimental groups.
Discussion
Improved therapies for oral squamous cell carcinoma, includ-
ing surgery, chemotherapy, radiotherapy, and immunotherapy, 
are currently being evaluated to determine their efficacy in 
promoting long-term, disease-free survival. Photothermal 
therapy is a novel noninvasive treatment approach and is rap-
idly being recognized as one of the most effective therapeutic 
strategies for targeting tumor cells specifically.
In this study, anti-HER2 nanobody-tagged gold-silica 
nanoshells were generated, and their photothermal potency 
was examined in KB and HeLaS3 cells. Our data demonstrated 
selective tumor destruction of more than 69.4% of KB (HER2-
positive) cells with no mortality in HeLaS3 (HER2-negative) 
cells. It should be noted that nonspecific binding of conjugated 
nanoshells and extra reagents was minimized by washing to 
prevent cell death following near-infrared laser radiation.
AB
Figure 3 (A) her2-positive KB cells exposed to anti-her2 immunonanoshells (nanobody-conjugated nanoshells). (B) cytotoxicity was observed in cells treated with near-
infrared laser. Images represent cells targeted with anti-her2 nanoshells only.
A B
Figure 4 (A) her2-negative heLas3 cells treated with anti-her2 immunonanoshells. (B) No cytotoxicity was observed in heLas3 cells following near-infrared laser 
treatment.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 5 MTT assay results for normal her2-positive (KB) and her2-negative (heLas3) cells before and after near-infrared laser irradiation. 
Abbreviation: NIr, near-infrared.
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Figure 6 MTT assay results for KB and heLas3 cells following treatment with her2-targeted nanobodies and near-infrared laser. 
Abbreviation: NIr, near-infrared.
Our current data highlight several advantages of 
nanobody-conjugated nanoshells compared with current 
treatments for oral squamous cell carcinoma. Nanobody 
labeling of nanoshells serves to increase nanoparticle 
specificity and therapeutic efficiency in vitro and is rapidly 
emerging as a new therapeutic class of immunonanoshells. 
For use in vivo, increasing nanoparticle specificity would 
be beneficial in that it would result in a higher accumula-
tion of nanoparticles in the target tissue. It should be noted 
that there is no resistance to photothermal application International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Figure 7 MTT assay results for KB and heLas3 cells exposed to bare nanoshells. Both cell types were treated with a near-infrared laser. 
Abbreviation: NIr, near-infrared.
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Figure 8 Anti-her2 immunonanoshells (nanobody-conjugated nanoshells) were added to KB and heLas3 cells, and the cells were treated with an near-infrared laser. 
An MTT assay was performed on both cell types and our results indicated that immunotargeted nanoshells can selectively induce specific cell death in vitro. 
Abbreviation: NIr, near-infrared.
for use in vivo. It has been observed that current tumor 
therapies can induce cancer cells to alter their cell surface 
marker expression; however, nanoparticles could localize to 
target cancer cells without causing any detectable cellular 
alterations. Furthermore, our toxicology results indicate 
that the anticancer effects of our immunonanoconjugate are 
limited to the areas exposed to near-infrared laser irradiation. 
The requirement for the presence of both nanoshells and 
laser light to induce cell death is promising for use in 
tumors in which local recurrence is often the most serious 
risk and the surrounding normal tissues perform critical 
functions. In conclusion, we demonstrate for the first time International Journal of Nanomedicine
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that immunonanoshells containing nanobody conjugates 
can be used to induce selective cancer cell death in vitro. 
In vivo studies are currently underway in mouse models of 
oral squamous cell carcinoma to determine the therapeutic 
efficacy of gold–silica nanobody immunonanoshells.
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